AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04123652 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
Description: An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours.
Study NCT02698878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lupin protein
Description: 19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
Study NCT02698878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
Study NCT01025206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-505
Description: Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
Study NCT03703479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous blood clot made from the patient own clot without any additive
Description: advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
Study NCT03761784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-3
Description: Once a day topical cream
Study NCT01719055 — intervention group
Intervention type: DEVICE
Intervention: neurostimulation system
Description: Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
Study NCT04155827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT
Description: Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
Study NCT02280187 — intervention group
Intervention type: PROCEDURE
Intervention: Spine Fusion
Description: All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
Study NCT04383717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole and isoprinosine
Description: oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
Study NCT04383717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin and hydroxychloroquine
Description: oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
Study NCT01405274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy treatment bi-weekly, delivered at the child's home
Study NCT03969316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block, Quadratus lumborum block
Description: The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
Study NCT02681406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHESS
Description: Smartphone based additions focused application, encouraging social support
Study NCT02698878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPHAISTOS unloading orthotic device
Description: Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
Study NCT02698878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPHAISTOS unloading orthotic device
Description: Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
Study NCT02681406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMC
Description: Brief telephone monitoring and counseling
Study NCT02587455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab - Trial Treatment
Study NCT02587455 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy - Standard Treatment
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACYW-135 conjugate vaccine
Description: Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//Hib vaccine
Description: DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//Hib vaccine
Description: DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Description: Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentavalent rotavirus vaccine
Description: Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
Study NCT04638660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Ophthalmic Solution 0.75%
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study NCT04638660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Ophthalmic Solution Vehicle (Placebo)
Description: Topical sterile ophthalmic solution
Study NCT03429660 — intervention group
Intervention type: OTHER
Intervention: Medical information
Description: The information collected are about :~* Introduction or non-introduction of treatment~* Cumulative dose of treatment~* Drug dispensation and withdrawal~* Hospitalization reason~* Safety information~* Demographic data (date of death)
Study NCT03781843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with lidocaine
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
Study NCT03781843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Genicular nerve block with saline
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
Study NCT03781843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Genicular nerve block with dextrose
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
Study NCT00687895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical algorithm and microscopy diagnosis of malaria
Description: Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides.
Study NCT02624674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-spectral Imaging Device (MSID)
Study NCT02737280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy
Description: High flow nasal cannula therapy with Airvo (TM, Fisher \& Paykel Healthcare) device
Study NCT02737280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedKit Finland - Usual oxygen therapy
Description: Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
Study NCT03917459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
Study NCT03917459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril matching placebo
Description: Placebo to Enalapril 10 mg film-coated tablets
Study NCT03917459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 10 mg film-coated tablets
Study NCT03917459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 matching placebo
Description: Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
Study NCT02505763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strategy with thoracic ultrasound
Description: This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
Study NCT03532061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamCare Program
Description: 6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
Study NCT03532061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Support Group
Description: 6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
Study NCT00376064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate and cabergoline/Octrotide and Somavert
Study NCT01971242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
Study NCT01971242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
Study NCT01622803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parallel stent
Description: bilateral parallel stent insertion (right and left side)
Study NCT01622803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Y-stent (BONASTENT M-Hilar)
Description: Bilateral Y-stent insertion (stent in stent type)
Study NCT03710005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascent
Description: Dehydrated Cell and Protein Concentrate injection
Study NCT03710005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard corticosteroid injection
Study NCT05687175 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire administration (PDQ-M, NRS, SF-36)
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, rubella (MMR) vaccine
Description: MMR vaccine at 12 months of age, Subcutaneous
Study NCT03761784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S6G5T-8
Description: Once a day topical cream
Study NCT04153344 — intervention group
Intervention type: OTHER
Intervention: Electro-oculogram
Description: Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
Study NCT02451111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
Study NCT02451111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
Study NCT02451111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
Study NCT00149734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron followed by placebo
Description: Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
Study NCT00149734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo followed by Ondansetron
Description: Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
Study NCT02170194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Training via Smart Phone
Study NCT02170194 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Text Messages
Study NCT01278836 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fasciocutaneous flap
Description: flaps which include skin, subcutaneous tissue, and the underlying fascia.
Study NCT00435864 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
Study NCT00154622 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: work hardening program
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, mumps, rubella (MMR) vaccine
Description: MMR vaccine at 12 months of age, Subcutaneous
Study NCT04153344 — intervention group
Intervention type: OTHER
Intervention: Full-field electroretinogram
Description: Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Description: Varicella vaccine at 12 months of age
Study NCT00697788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine
Description: Varicella vaccine at 12 months of age
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine at 15 to 18 months of age
Study NCT03537508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine at 15 to 18 months of age
Study NCT00784017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Description: 5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
Study NCT00784017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant asparaginase
Description: 5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
Study NCT01001689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling + exercise groups
Description: Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
Study NCT06142591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 10mg
Description: 10mg of oxycodone was added to Octenisept in the wound dressing.
Study NCT03058783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-124 Lotion
Description: IDP-124 Lotion, twice-daily application
Study NCT03058783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-124 Vehicle Lotion
Description: IDP-124 Vehicle Lotion, twice-daily application
Study NCT06142591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 20mg
Description: 20mg of oxycodone was added to Octenisept in the wound dressing.
Study NCT04734392 — intervention group
Intervention type: PROCEDURE
Intervention: TAVR
Description: TAVR implantation in cusp overlay technique
Study NCT00573768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine 2.32% gel
Description: Diclofenac diethylamine 2.32% gel twice daily
Study NCT00573768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle 2 times daily
Study NCT00573768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine 2.32% gel / Placebo
Description: Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
Study NCT04442009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group SCPB
Description: In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT03840889 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: he different modes of active data collection:~* Data collection by telephone~* Data collection by mail~* Collection from discharge database summaries (PMSI)
Study NCT02018068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote control
Description: When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
Study NCT02018068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: At bedside care
Description: When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
Study NCT02670720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avoralstat
Study NCT02472873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration and Sclerotherapy of endometriomas.
Description: Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
Study NCT02472873 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cystectomy of endometriomas.
Description: cystectomy of endometriomas during laparoscopy